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Background: Triple infection (TI) with HIV-1, HCV, and HBV (TI) is highly prevalent in intravenous drug
users (IDUs). These TI patients have a faster progression to AIDS, and even after antiretroviral therapy
(ART) the prognosis of their disease is poor. The use of microRNA (miRNA) to silence genes holds potential
applications for anti-HCV therapy.
Methods: We analyzed the role of human miRNAs (hsa-miRs) in TI by computational analyses for HCV,
HIV-1, and HBV showing identity to these three viral genomes.
Results: We identified one unique miRNA, hsa-miR-3065-3p, that shares significant mutual identity to these
three viral genomes (6183%). In addition, hsa-miR-99, hsa-miR-548, and hsa-miR-122 also showed mutual
identity with these three viral genomes, albeit at a lower degree (5288%).
Conclusion: Here, we present evidence using essential components of bioinformatics tools, and hypothesize
that utility of hsa-miR-3065-3p and perhaps miR-548 would be potential antiviral therapeutic agents in the
treatment of TI patients because it shows near perfect alignment in the seed region for all three viruses. We
also make an argument that current proposed therapy with hsa-miR-122 may not be the optimal choice for
HCV patients since it lacks essential gene alignment and may be harmful for the patients.
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M
icroRNAs (miRNAs) have emerged as key
molecules in the regulation of a multitude of
biological processes, from plants to animals,
alongside approximately 20,00030,000 coding genes
(13). The regulation of miRNA expression is tightly
controlled, and often the same rules and regulations that
govern coding gene expression apply to miRNAs. Similar
to coding genes, the alteration of levels of the temporal
and differential expressions of each of the miRNA clearly
affects the proper development and function of the tissue
where it is expressed (46). MiRNAs, small 1923
base pair (bp) double-stranded RNA molecules that
are endogenously produced, are known to regulate at
least one-third of all human genes (1, 49). They are
(page number not for citation purpose)
ORIGINAL ARTICLE
Libyan J Med 2012. # 2012 Ambreen Khokhar et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction
in any medium, provided the original work is properly cited.
1
Citation: Libyan J Med 2012, 7: 19774 - http://dx.doi.org/10.3402/ljm.v7i0.19774
also known to serve as a physiological and intracellu-
lar response to detect small double-stranded RNA
(dsRNA), leading to the silencing or down-regulation
in a sequence-specific manner of gene expression (3, 7).
These RNA-based small molecules provide molecular
immune defenses when the body is faced with challenges
from transgene, RNA, or DNA viruses, as well as
from transposons and aberrant miRNAs (3, 79). Both
exogenous hosts in small interfering RNAs (siRNAs)
and endogenously expressed miRNA molecules trigger
RNA interference (RNAi) in eukaryotic cells (13). Until
now (March 2012), researchers have identified 1,527
different human miRNAs (hsa-miRs) (Sanger Database
version 18), and it has come to be regularly accepted
that cellular gene regulation is significantly impacted by
cellular miRNAs. Continually mounting evidence sug-
gests that miRNAs control both RNA and DNA viruses
by controlling their replications (9, 10). Evidence from
our own laboratory has led us to believe that miRNAs
can target the specific genetic material of invading
viruses and serve as molecular immune systems (3, 8,
9). Triple infection (TI) with Human Immunodeficiency
Virus Type-1 (HIV-1)/Hepatitis C Virus (HCV)/Hepatitis
B Virus (HBV) are relatively less common among HIV-1
infected individuals, and these ‘triple’ infected individuals
progress to AIDS relatively more quickly than mono or
dual coinfected patients (e.g. HIV-1/HBV or HIV-1/HCV)
(1114). In our search for one or more hsa-miRs that may
share mutual identity to all three viruses, and that can be
utilized as a potential silencing agent for all three viruses
in TI patients, we carried out alignments with the full-
length genomes of HCV/HIV-1/HBV against the known
hsa-miRs in the Sanger database. The well-characterized
hsa-mir-122 is also discussed here in the light of the
new findings, including its role in HCV therapy (12, 13).
Currently, hsa-miR-122 is the major therapeutic miRNA
against HCV, but it does not target the other two viruses.
We present evidence that hsa-miR-3065-3p shares sig-
nificant mutual identity with all three viruses, and that
it may have a potential therapeutic application in TI
patients, as well as in HCV mono-infected individuals
(1216).
Materials & methods
Mature miRNA database and gene alignment
Finding miRNAs that share identities with all three
viruses can potentially be a tool to quell the triple
infection. At the time of our studies, 1,527 mature human
miRNAs (hsa-miR) were listed in the Sanger database.
By utilizing the human miRBase sequences database
(http://www.mirbase.org, version 18.0), the hsa-miR se-
quences were aligned with each of the three viral
genomes individually (i.e. HCV: Accession#NC_004102,
HIV-1: Accession #NC_001802, and HBV: Accession
#NC_003977). Before analysis, each U of hsa-miRs
was converted to a T. The reference genome sequences
of these three viruses were obtained from http://www.
ncbi.nlm.nih.gov/. Following this, we utilized multiple
alignment tools to search for miRNA that shared
identities with all three viruses as described previously
(17).
Determination of microRNA alignment to viral
sequences
To determine the suitability of each of the hsa-miRs as
a potential therapeutic agent, we developed and refined
the algorithm that incorporates the three critical elements
that increases the suitability of a miRNA as a success-
ful silencing agent. These include: 1) the length of the
complementary pairing of human miRNAs. In this case,
we downloaded the available miRNAs from miRbase
data and aligned with HCV, HIV-1, and HBV genomes,
as miRNA silencing requires a minimum of 19 bp (9, 17,
18); 2) a perfect or near-perfect alignment at miRNA seed
sequences located at the 3’-untranslated region (3’UTR)
base pairs 28 (9, 18) further signals a successful silencing
match, and 3) a hairpin stem-loop secondary structure
(46). Recently, the above information was detailed by us
elsewhere (9, 18). The 80% degree level for the identity
of the sequence of miRNAs with the three virus genome
was considered as significant.
Hairpin stem-loop secondary structure
The ‘mature’ and ‘stem-loop’ sequences for hsa-miR-122
and hsa-miR-3065 were obtained from the ‘miRBase’
database (http://www.mirbase.org). The ‘mature’ se-
quences of the miRNAs are part of their ‘stem-loop’
sequences. The mature sequences, in vivo, result from
excision of the middle (loop) region and the end of
the ‘stem-loop’ sequences by DROSHA, an enzyme
that allows the export of miRNAs from nucleoplasm to
cytoplasm. The miRBase database provides both mature
as well as stem-loop sequences for each miRNA and
two mature sequences (5’ and 3’) for every stem-loop
sequence of a miRNA. When both 5’ and 3’ mature
sequences were aligned with stem-loop sequences for
the same miRNAs,100% alignment was obtained with
certain regions of the stem-loop sequences. The 5’ and 3’
mature sequences comprise the portions between the
middle and the ends on a stem-loop sequence as shown
in Fig. 1. The 5’ and 3’ mature sequences are almost
always complementary so that they bind together and
the middle portion of the stem-loop sequence bulges out,
which is further removed by DROSHA and presumably
degraded (79).
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Results
Human miRNA alignment
The target genes for the hsa-miRNAs were identified by
retrieving the whole genome for HCV, HIV-1, and HBV
individually from PubMed (http://www.ncbi.nlm.nih.gov/
pubmed/). Each human miRNA (hsa-miR) found within
the Sanger database (version 18.0) was determined to
be identical to the Coding DNA Sequence (CDS) of the
target gene by matching with 1923 bp. The lengths of the
1923 bp hsa-miRs were identical to those of the target
genes of the three viruses, as identified by alignments,
according to the full length CDS of the three viral genes
using the specific alignment tools.
hsa-miR-3065 identity with HCV, HIV-1, and HBV
Here, we show via computational analysis that hsa-
miR-3065-3p could be used as a therapeutic marker for
treatment of triple infections (i.e. HCV, HIV-1, and HBV).
The main focus of this study is hsa-miR-3065-3p and not
hsa-miR-122, hsa-miR-99, or has-miR-548.
Through the computational analyses described in the
Methods section in this article, we found that 42 hsa-miRs
showed80% identity to HCV (Supplemental Table 1), 41
miRNAs exhibited80% identity to HIV-1 (Supplemen-
tal Table 2), and 37 miRNAs shared80% identity to
HBV (Supplemental Table 3). We also performed compu-
tational analysis for 1,527 hsa-miRs to assess their align-
ment with all six genotypes of HCV and found that
hsa-miR-3065-3p was the only miRNA that aligned with
HCV genotype 1, as well as with HIV-1 and HBV. It has
also been reported that HCV genotype 1 is globally
prevalent (1921). As summarized in Table 1, we also
show that three hsa-miRs (miR-3065-3p, miR-99, and miR-
548) exhibited a significant mutual identity to genomic
sequences of these three viruses. In addition, the homo-
logies in the seed sequences at 3’UTR bps of hsa-miR-
3065-3p were also relatively good but not perfect as they
exhibited a non-homologous base pair match at the seed
Fig. 1. miRNAs are initially transcribed as several hundred nucleotide long primary or pri-miRNAs and are then processed
to approximately 60-nucleotide (nt) hairpin pre-miRNAs in the nucleus by the double-stranded RNA (dsRNA)-specific
ribonuclease (Drosha). The ribonuclease Drosha requires a dedicated dsRNA-binding protein to convert long, nuclear pri-
miRNA transcripts into shorter pre-miRNA hairpin stem-loops. The pre-miRNAs are exported to cytoplasm where they are
further excised by a RNA-induced silencing complex (RISC) enzyme. These miRNAs are further processed into numerous
specific 19 to 23 nt miRNAs, with the ability to target various endogenous and exogenous genes (8).
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residue position #7 for HCV (Table 1). In addition, we also
discovered non-homologous bases at position #6 for HIV-
1 and position #78 for HBV. Of note, the most important
sequences that should be identical are the first four bps of
the seed sequence (5, 6, 22, 23) between the hsa-miRNA
and the target sequence. Therefore, as shown in Table 1, in
the case of hsa-miR-3065-3p, evidence has shown perfect
homologies for all three viruses at the first four bps of the
seed sequences (i.e. 25 bp). Interestingly, hsa-miR-122
exhibited imperfect homologies in the seed sequences
for all three viruses, even for HCV (23). The seed region
is the most evolutionarily conserved region of miRNAs
and is the region most complementary to target sites in
3’UTRs. In many cases, only a seed match is considered
sufficient for gene silencing. Many target prediction
algorithms are based around such a model, though
increasing evidence demonstrates that targeting can
also be mediated through sites other than the 3?-UTR
and that seed region base pairing is not always required
(5, 6, 2224). Therefore, despite the importance of the
seed region, the 3?-end of a miRNA also contributes
to effective binding in roughly 2% of all preferentially
Table 1. Human miRNA showing significant mutual identity with HCV, HIV-1, and HBV
No. miRNA Sequence alignment Gene
Seed sequence
homology % Identity








hsa-miR-3065-3p 2058 CAGCACTCAGGCAAGCTATTCTGTGTTGGGG 2088
HBV jjjjjj jj.j.jjj jjjjjj.j
2 CAGCAC-----CAGGATAT----TGTTGGAG 23
HBV-GP4 19/31 61.3





















hsa-miR-99a 5381 AGCCAGTAGATCCTAGA-CTAGAG 5403












4 hsa-miR-548a 2202 ACCATCAATTA------CACCA 2217
HCV jjjj jjjjjj jjjjj
5 ACCA-CAATTACTTTTGCACCA 25
HCV-GP1 15/22 68.2
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conserved sites (5, 6, 9, 23). Furthermore, some validated
miRNA target sites do not have a complete seed match
but instead exhibit 1112 continuous base pairs in the
central region of the miRNA (25). However, an overall
high identity of hsa-miR-3065-3p to all three viruses
may still make this miRNA a strong candidate against
all three viruses. Of note, it is significant that anti-HCV
and anti-HIV-1 effects discovered in silico may be effec-
tive enough to offset the two bps non-homologous pairing
for HBV.
hsa-miR-122 identity with HCV, HIV-1, and HBV
We focus on HCV and miRNA because the first targeted
miRNA therapy for HCV, known as miravirsen or
SPC3649, is now being tested in a Phase 3 clinical trial
of previously untreated chronic hepatitis C (CHC)
patients by Santaris Pharma. In 2009, miR-122-based
molecular therapy was the first to utilize miRNA in
clinical trials involving humans; in 2012, this therapy
entered Phase 3 of its clinical trial (21, 24). The hsa-miR-
122 was named miravirsen by California based Santaris
Pharma, which initiated the trials in 2009.
hsa-miRs: 99 and 548 identity with HCV,
HIV-1, and HBV
The other two miRNAs, hsa-miR-99 and hsa-miR-548,
did show, respectively, 79 and 68% identity with HCV,
but their identity with the other two viruses (HIV-1 and
HBV) was only significant with other branches of hsa-
miRs (Table 1), which may not be important in regulating
the viral replications of any of the three viruses. For
instance, hsa-miR-99a showed 79% identity to HCV
and 71% identity to HIV-1; however, 68% identity to
HBV was observed in relation to hsa-miR-99b, a branch
of miR-99.
Similarly, hsa-miR-548 also showed significant identity
with each of the three viruses: 68% with HCV, 80%
with HIV-1, and 88% with HBV, and their importance in
HBV or HIV-1 treatment as a therapeutic marker cannot
be ruled out as the identity between hsa-miR-548b
and hsa-miR-548s and viral target sites is 80% and above
(Table 1). Furthermore, miR-548 showed perfect align-
ment at the first four bases of the seed sequences, making
it a significant anti-TI therapeutic miRNA.
Discussion
In our current investigation, we have carried out align-
ments of human hsa-miRNAs currently in the miR
database with full-length genomes of the three viruses
that share mutual identities. Our analyses identified that
hsa-miR-3065-3p shares significant mutual identity with
all three viruses. The well characterized hsa-mir-122 is
also discussed here in the light of the new findings,
including its role in HCV therapy (12, 13, 21, 22, 24).
Currently, hsa-miR-122 is the major therapeutic miRNA
against HCV but it does not target other two viruses.
We present evidence that hsa-miR-3065-3p may have a
potential therapeutic application in TI patients, as well as
in HCV mono-infected individuals (1216).
HCV
HCV is an RNA virus and a member of the Flaviviridae
family that infects the liver (26). HCV is a major cause
of CHC infection and of hepatocellular carcinoma (HCC:
25). According to the World Health Organization,200
million people are infected with HCV and between three
and four million persons are newly infected each year,
which leaves a global total of 170 million chronic carriers
at risk for developing liver cirrhosis and/or HCC (26).
Triple infection and hsa-miR-3065 identity
All TI viruses share similar modes of transmission that
include blood to blood contact, sexual contact with an
infected person, or vertical (mother to child) transmission.
Pakistan has an overall HIV-1 prevalence of 0.1%, but
within certain high risk groups, such as IDUs and MSM
(men who have sex with men); concentrated HIV-1
epidemics exist in certain parts of PakistanAfghanistan
border areas and amongst the refugees where the pre-
valence of HIV is 23% (46, 27, 28). Limited data exist on
the prevalence of HIV-1, HCV, and HBV in neighboring
Afghanistan (27, 28). IDUs, MSM, commercial sex work-
ers, migrant workers, and prisoners are recognized as
subgroups at high risk for TI among the Afghan natives
and among refugee populations (27). A major high risk
behavior observed among infected participants in this
study was the high drug abuse in TI patients  28.4%. Out
of these drug users, some individuals reported only
injecting drugs (IDUs, 12.8%) while others admitted to
both smoking/inhaling as well as injecting drugs (18.5%).
A significant correlation was observed between drug use
and HIV-1 infection in a recent study (27).
As shown in Table 1, hsa-miR-3065-3p exhibited
significant identity with all three viruses. These identities
were 83% for HCV, 77% for HIV-1, and 61% for HBV
and provided a strong indication that the affinities
between the inhibitory miRNA and the mRNAs of the
homologous sequences in all three viral genomes may
markedly silence all viruses. However, hsa-miR-3065-3p
may indirectly be beneficial by silencing of HIV-1, which
causes immunodeficiency and may be at least partially
responsible for increasing the replications of HCV and
HBV (29). Most importantly, for all three viruses, the
seed sequence rules for efficient silencing described in
the literature are perfectly satisfied, suggesting a strong
silencing effect (5, 6, 9, 23).
Of note, miRNAs are double-stranded RNAs with
single base overhangs at both ends; therefore, identities
should have a similar impact on the mRNA degrada-
tion depending on the orientation of miRNA, binding as
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sense or antisense strands to the RNA-induced Silenc-
ing Complex (RISC) (30). The randomness of sense or
antisense strands that enter the RISC to degrade a target
mRNA requires analyses of identity of each miRNA (30).
HCV and hsa-miR-122
An intense interest in the development of a miRNA-based
therapy for HCV infection and hsa-miR-122 has received
considerable attention. The potential value of miRNA in
antiviral immunity was first proposed in 1997 by Bagasra
et al. (30, 31), but only very recently has the capacity of
hsa-miRNA for both viral promotion and deterrence been
demonstrated, mainly in the case of HCV infection (12, 13,
2124, 32, 33). Hsa-miR-122 is a liver-specific miRNA that
positively regulates HCV RNA abundance and appears
to be essential for the production of infectious HCV.
A genetic approach has demonstrated that the ability of
hsa-miR-122 to enhance yields of the infectious virus is
dependent upon two hsa-miR-122-binding sites near the 5’
end of the HCV genome, S1 and S2 (12, 2124). Viral RNA
with base substitutions in both S1 and S2 failed to produce
infectious viruses in transfected liver cells, while the virus
production was rescued to near-wild-type levels in cells
supplemented with a complementary hsa-miR-122 mutant.
A comparison of mutants with substitutions in only one
site revealed S1 to be dominant, but the S1 mutant did not
produce high virus yields in liver cells supplemented with
wild-type hsa-miR-122. According to Jangra et al. (12),
translation of HCV RNA was reduced over 50% by muta-
tions in either S1 or S2, and was partially rescued by the
transfection of the complementary hsa-miR-122 mutant
(12, 13). However, unlike the case for viral replication, both
sites functioned equally in regulating translation. These
investigators concluded that hsa-miR-122 promotes repli-
cation by binding directly to both sites in the HCV
genomic RNA and, at least in part, by stimulating in-
ternal ribosome entry site (IRES)-mediated translation
(12). However, a comparison of the replication capacities
of the double-binding-site mutant and an IRES mutant
with a quantitatively equivalent defect in translation
suggested that the decrement in translation associated
with the loss of hsa-miR-122 binding was insufficient to
explain the profound defect in virus production by the
double mutant. Hence, hsa-miR-122 acts at an additional
step in the virus life cycle by producing infectious HCV
particles.
In a recent study (13), researchers investigated the effect
of hsa-miR-122 on the mevalonate pathway and showed
that this miRNA does not affect HCV RNA abundance
directly through mevalonate pathway in the animal liver.
They determined that over-expression of hsa-miR-122
enhanced viral RNA accumulation without affecting
genes in the mevalonate pathway, such as the 3-hydroxy-
3-methylglutaryl-coenzyme reductase (HMGCR) gene.
However, inhibition of hsa-miR-122 decreased both HCV
RNA and HMGCR RNA abundance with little effect on
the rates of HCVand HMGCR RNA synthesis, and loss of
HCV RNA could not be restored by isoprenoid inter-
mediate metabolites. Their findings suggest that miR-122
modulates viral RNA abundance independently of its
effect on isoprenoid metabolism. Of note, the mevalonate
pathway is the main pathway that converts mevalonate to
cholesterol and isoprenoid intermediates. These investiga-
tors (13) evaluated the physiological effects of hsa-miR-122
sequestration and concluded that it decreased expression
of transcripts encoding proteins of this pathway, such as
HMGCR and Squalene epoxidase. Because these tran-
scripts do not contain hsa-miR-122-binding sites, it is as-
sumed that hsa-miR-122 regulates the expression of
HMGCR by the down-regulation of an inhibitor for these
genes.
Currently, anti-HCV treatment based on miR-122
inhibition by antisense oligonucleotide anti-miR-122
(miravirsen or SPC3649) is the first miRNA-targeting
treatment in human clinical trials to treat previously
untreated CHC patients infected with HCV. Conversely,
there is no miRNA-targeted therapy (2124). Data
from the Phase 2a study also showed that the mean
change from baseline in HCV RNA (log10 IU/mL) at 10
weeks after initiation of therapy was0.57,2.16,
and2.73 in the 3, 5, and 7 mg/kg miravirsen dose
groups, respectively, compared to the0.01 level ob-
served in the placebo group (21). Miravirsen was designed
to recognize and interfere with hsa-miR-122, a liver-
specific miRNA that HCV requires for replication.
Studies to date have found that the drug appears
safe, and that it reduces the HCV viral load in the liver
and blood of chronically infected chimpanzees (21). On
the contrary, for HIV-1 and HBV there is no miRNA-
targeted therapy, and hsa-miR-122 does show limited
identities to HIV-1 and HBV (Table 1). Interestingly,
hsa-miR-122 is only 17 bp long, it has a non-homologous
bp match at seed residue position #4 to HCV, and to
be a potential candidate for gene-based therapy, the first
four bps of the seed sequence should be identical (23, 24),
which they are not (Table 1). Furthermore, a synergistic
anti-TI effect of hsa-miR-3065-3p may inhibit the three
viruses in a multi-target fashion, where downregulation
of one virus may down-regulate the other two. Hence,
through our computational analysis, we propose the
utility of hsa-miR-3065-3p in TI patients as a potential
therapeutic agent infected with HCV/HIV-1/HBV It is
worth mentioning that hsa-miR-122 has been the subject
of intensive investigations around the globe, and it
has been fairly well established that this miRNA ap-
pears to play a crucial role in upregulating intracellu-
lar HCV replication in hepatic cells (12, 13, 21, 22, 24).
We also carried out genome/miRNA alignment to
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determine the degree of identity of hsa-miR-122 and
discovered that even though this miRNA does share a
significant (88%) identity to HCV, it does not appear
to follow the basic rules in relation to having the
minimum 19 bp required for functional miRNA expres-
sion in vivo and in vitro (9, 21), since it has 17 miRNAs.
In addition, the seed sequence rules for efficient silenc-
ing described in the literature are not entirely satisfied
(5, 6, 9). Therefore, it lacks perfect identity at seed
sequence bp #4 for HCV (located at 3’UTR 28).
Moreover, it is 17 bp long and 15 nucleotides are
homologous to HCV (Table 1), making it an unlikely
candidate for therapeutic utility. Since this same miRNA
may target many other mRNAs, unwanted side effects
may occur (9). Furthermore, hsa-miR-122 shares a much
lesser identity to HIV-1 and HBV (53 and 71%, respec-
tively), which potentially makes it less effective as a
therapeutic treatment agent against TI patients (1416).
These data suggest the need for alternate miRNAs for
targeting CHC subjects.
A study that investigated 185 seropositive patients’
sera for HCV and correlated hsa-miR-122 expression and
HCV load in liver samples found that hepatic miR-122
expression was not correlated with the viral load (32).
Therefore, miR-122, by itself, is not a critical molecular
target for HCV therapy. Hsa-miR-122 expression is
inversely correlated with both functional and histopatho-
logical liver damage and is believed to stimulate HCV
replication through interaction with two adjacent sites
downstream of stem loop I (SLI) within the HCV
5’UTR. Recently, it has been demonstrated that although
the approach of host-factor hsa-miR-122 antagonism
has potential for HCV therapy, and is being tested in
clinical trials, the reduced antiviral effect by single
mutation in S1 supports the reevaluation of this approach
as monotherapy for future HCV treatment (33). There-
fore, identification of host cellular RNA insertions in the
HCV genome might facilitate understanding of virus
host interactions and can contribute to the identification
of other host cellular interacting partners as future drug
targets.
hsa-miRs: 99 and 548 identity with HCV,
HIV-1, and HBV
The hsa-miR-99 showed reasonable alignments of 79,
71, and 68% identities, respectively, with all three viruses
but lacked significant identities at the seed sequences
and was only significant with other branches of hsa-miRs
(Table 1). This may not be important in regulating the
viral replications of all three viruses and we did not
consider it to be of any important therapeutic benefit.
On the contrary, hsa-miR-548 showed 68, 80, and 88%
identities with HCV, HIV-1, and HBV, respectively, and
100% identities at the seed sequence with the other two
viruses (HIV-1 and HBV), which make it an important
anti-TI miRNA, in particular, when it showed significant
identities to HIV-1 and HBV (i.e. 80 and 88%, respec-
tively). Since dual infection with HIV-1 and HBVare much
more common than the TI, this miRNA can also be
a valuable therapeutic agent in TI as well as in dual in-
fected patients (22, 23). Li et al. (29) have shown that
HIV-1 may accelerate HBV progression by lowering CD4
count, weakening HBV-specific immunity, increasing the
development of HBV mutants, and causing immune
activation. On the contrary, HBV may enhance HIV-1
replication by activating HIV long terminal repeat with X
protein (HBX) and cause immune activation in synergy
with HIV-1.
Liang et al. (34) have carried out a genome-wide analysis
of hsa-miR-548 and have shown that this miRNA belongs
to a larger, poorly conserved primate-specific miRNA gene
family. They detected 69 human mir-548 genes located in
almost all human chromosomes whose widespread dis-
tribution pattern implicates the evolutionary origin from
transposable elements. Higher level of nucleotide diver-
gence was detected between these human miRNA genes,
which mainly derived from divergence of multicopy pre-
miRNAs and homologous miRNA genes. The location of
mir-548 gene family members is detected in all human
chromosomes except chromosomes 19 and Yand over 30%
of the members are located in chromosomes 6, 8, and X.
Furthermore, functionally miR-548 miRNAs are linked to
various signaling pathways, including MARK, Wnt in-
sulin, calcium, and p53 signaling pathways as well as to
various cancers, including melanoma, colorectal, renal,
small cell lung cancer, and glioma. However, no previous
report has shown its involvement in quelling triple infec-
tions. Therefore, this is the first report where we are
presenting potential use of miR-548 as a therapeutic agent
in TI.
In this study, we present the theoretical evidence that by
utilizing a strict thermodynamic algorithm, hsa-miR-122
does not have the efficient HCV-promoting effect as has
been suggested by numerous investigations (9, 12, 13, 21,
22, 24). It is also evident that the role of hsa-miR-122 as a
potential antiviral agent in HCV therapeutics still needs
further investigation. We analyzed the identity of hsa-miR-
3065-3p through computational analysis and came to the
conclusion that it is perhaps a better miRNA than hsa-
miR-122 as a therapeutic agent for HCV infection alone or
for treatment of TI patients suffering from HCV, HIV-1,
and HBV. We also determined that has-miR-30653p fulfills
the three important criteria with the three viruses. How-
ever, neither of the two miRNAs (i.e. hsa-miR-3065-3p and
hsa-miR-122) exhibited 100% identity with HCV. Hsa-
miR-122 shows an imperfect identity at seed residue
position #4 and hsa-miR-3065-3p shows an imperfect
identity at seed residue position #7 in the seed sequence
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(28 bps) to the HCV genome (Table 1). The most
important sequences that should be identical are the
first four bps of the seed sequence (18) between the hsa-
miRNA and the target sequence. Therefore, as shown
in Table 1, in the case of hsa-miR-3065-3p, perfect
homology is seen at the first four bps of the seed sequences
(i.e. 25 bp), making it a relatively more important
potential candidate for gene-based therapy against HCV
alone and TI. However, hsa-miR-122 exhibited imperfect
homologies in the seed sequences for all three viruses,
even for HCV (Table 1). Interestingly, both miRNAs
target the GP1 site, which is an important step in viral
entry (21, 24).
Conclusion
We conclude that hsa-miR-3065-3p could be utilized as a
potential target for antiviral therapeutics for TI patients
and also in HCV mono-infected patients. Furthermore,
miR-548 may be an alternate therapeutics agent in TI and
HIV-1 HBV dual infected patients.
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